Level Four Advisory Services’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.8M | Buy |
132,234
+485
| +0.4% | +$108K | 0.94% | 15 |
|
|
2025
Q4 | $30.1M | Buy |
131,749
+2,631
| +2% | +$599K | 0.99% | 16 |
|
|
2025
Q3 | $29.9M | Sell |
129,118
-4,288
| -3% | -$873K | 1.02% | 16 |
|
|
2025
Q2 | $24.8M | Buy |
133,406
+4,041
| +3% | +$751K | 0.91% | 18 |
|
|
2025
Q1 | $27.1M | Buy |
129,365
+2,216
| +2% | +$431K | 1.11% | 11 |
|
|
2024
Q4 | $22.6M | Sell |
127,149
-7,570
| -6% | -$1.39M | 0.92% | 19 |
|
|
2024
Q3 | $27.5M | Buy |
134,719
+11,459
| +9% | +$2.14M | 1.16% | 11 |
|
|
2024
Q2 | $21.1M | Sell |
123,260
-11,585
| -9% | -$1.92M | 0.95% | 13 |
|
|
2024
Q1 | $20.9M | Buy |
134,845
+2,728
| +2% | +$470K | 1.15% | 10 |
|
|
2023
Q4 | $20.5M | Buy |
132,117
+1,834
| +1% | +$267K | 1.15% | 10 |
|
|
2023
Q3 | $19.4M | Sell |
130,283
-45,817
| -26% | -$6.73M | 1.25% | 8 |
|
|
2023
Q2 | $23.7M | Sell |
176,100
-45,730
| -21% | -$6.71M | 1.43% | 8 |
|
|
2023
Q1 | $35.4M | Buy |
221,830
+82,694
| +59% | +$12.6M | 2.32% | 5 |
|
|
2022
Q4 | $22.5M | Buy |
139,136
+43,265
| +45% | +$6.63M | 1.67% | 6 |
|
|
2022
Q3 | $12.9M | Sell |
95,871
-2,787
| -3% | -$400K | 1.25% | 11 |
|
|
2022
Q2 | $15.1M | Sell |
98,658
-6,550
| -6% | -$1M | 1.43% | 7 |
|
|
2022
Q1 | $17.1M | Buy |
105,208
+1,458
| +1% | +$212K | 1.34% | 8 |
|
|
2021
Q4 | $14M | Buy |
103,750
+27,946
| +37% | +$3.3M | 1.07% | 10 |
|
|
2021
Q3 | $8.18M | Sell |
75,804
-14,660
| -16% | -$1.68M | 0.85% | 22 |
|
|
2021
Q2 | $10.2M | Buy |
90,464
+10,047
| +12% | +$1.13M | 0.7% | 25 |
|
|
2021
Q1 | $8.7M | Sell |
80,417
-5,436
| -6% | -$581K | 0.68% | 24 |
|
|
2020
Q4 | $9.2M | Sell |
85,853
-6,863
| -7% | -$660K | 0.74% | 19 |
|
|
2020
Q3 | $8.12M | Sell |
92,716
-8,236
| -8% | -$775K | 0.63% | 27 |
|
|
2020
Q2 | $9.89M | Buy |
100,952
+32,191
| +47% | +$2.83M | 0.77% | 18 |
|
|
2020
Q1 | $5.24M | Buy |
68,761
+10,679
| +18% | +$910K | 0.63% | 31 |
|
|
2019
Q4 | $17.2M | Buy |
58,082
+2,339
| +4% | +$194K | 0.68% | 29 |
|
|
2019
Q3 | $4.22M | Buy |
55,743
+14,692
| +36% | +$1.01M | 0.44% | 48 |
|
|
2019
Q2 | $2.98M | Buy |
41,051
+1,108
| +3% | +$87.1K | 0.3% | 74 |
|
|
2019
Q1 | $3.22M | Sell |
39,943
-1,632
| -4% | -$134K | 0.35% | 66 |
|
|
2018
Q4 | $3.83M | Buy |
41,575
+1,203
| +3% | +$106K | 0.48% | 50 |
|
|
2018
Q3 | $3.82M | Sell |
40,372
-4,664
| -10% | -$442K | 0.41% | 63 |
|
|
2018
Q2 | $4.17M | Sell |
45,036
-10,022
| -18% | -$979K | 0.3% | 77 |
|
|
2018
Q1 | $5.21M | Sell |
55,058
-81
| -0.1% | -$8.9K | 0.4% | 57 |
|
|
2017
Q4 | $5.33M | Sell |
55,139
-140
| -0.3% | -$13.2K | 0.41% | 55 |
|
|
2017
Q3 | $4.91M | Buy |
55,279
+10,465
| +23% | +$797K | 0.44% | 52 |
|
|
2017
Q2 | $2.91M | Sell |
44,814
-13,959
| -24% | -$938K | 0.45% | 56 |
|
|
2017
Q1 | $3.82M | Sell |
58,773
-826
| -1% | -$51.9K | 0.39% | 59 |
|
|
2016
Q4 | $3.73M | Buy |
+59,599
| New | +$3.64M | 0.48% | 38 |
|
Other funds holding ABBV
VCM
VPM
Level Four Advisory Services's ABBV Position: Q1 2026 in Review
Level Four Advisory Services increased its AbbVie (ABBV) stake by 0.37% in Q1 2026, buying an estimated $108K and bringing the position to 132,234 shares worth $28.8M. The position accounts for 0.94% of the portfolio, ranked #15.
Level Four Advisory Services first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. The position peaked at $35.4M in Q1 2023. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Level Four Advisory Services held 132,234 shares of AbbVie worth $28.8M as of Q1 2026.
- Level Four Advisory Services bought 485 AbbVie shares in Q1 2026, an estimated $108K.
- AbbVie made up 0.94% of Level Four Advisory Services's portfolio in Q1 2026, its #15 holding.
- Level Four Advisory Services first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
- Level Four Advisory Services's AbbVie position peaked at $35.4M in Q1 2023.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Level Four Advisory Services's 13F filing for Q1 2026, filed 14 May 2026.